K. Rene Ward
Associate Director, Public Relations and Internal Communications
3902 Gene Field Road
St. Joseph, Missouri 64506
Value Through Innovation23 May 2013
November 15, 2012
New ULTRA Duramune vaccines are the first and only 1/2 mL vaccine line
New ULTRA Duramune vaccines are the first and only 1/2 mL vaccine line
Research innovation from Boehringer Ingelheim creates revolutionary low-dose vaccines to improve overall vaccine experience for dogs
Boehringer Ingelheim Vetmedica, Inc. (BIVI), announces the launch of the ULTRA™ Duramune®, a new canine vaccine line with 50 percent less volume per dose. The ULTRA Duramune line offers disease protection, patient comfort and safety, through innovative improvements to the vaccine manufacturing process.
The first of its kind, the ULTRA Duramune line is the next generation of vaccines manufactured with PureFil™ Technology, which includes improved purification processes and tighter manufacturing profiles, resulting in more serial-to-serial consistency. In addition, PureFil Technology is designed to reduce vaccine reactions associated with extraneous proteins and cellular debris.
"By removing extraneous proteins and cellular debris and reducing dose volume by 50% compared to most canine vaccines, ULTRA Duramune vaccines are developed for a more comfortable injection," says Dave Hustead, DVM, global brand manager, pet vaccines, BIVI. “Our new vaccines are built on the foundation of the original Duramune Max vaccines, featuring the same proven level of efficacy the industry has come to expect.”
ULTRA Duramune contains the same level of potency as Duramune® Max. Through the innovation of BIVI scientists and advancements to PureFil Technology, ULTRA Duramune helps veterinarians practice best medicine by improving the total vaccine experience for patients and pet owners.
"ULTRA Duramune is like no other vaccine, creating the opportunity to revolutionize the way veterinarians protect dogs against infectious diseases," says Hustead.
ULTRA Duramune will be available in core and non-core combinations, many of which are newly formulated to better align with current AAHA vaccine guidelines.
For more information on the ULTRA Duramune vaccine lines, please visit: www.BIVIULTRADuramune.com.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.
In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.
For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.
Reference
1. Data on file at Boehringer Ingelheim Vetmedica, Inc.
